[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335862-105":59,"doc-detail-335862-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-stat3-in-tumor-associated-antigen-presenting-cells-as-a-strategy-for-kidney-and-bladder-cancer-immunotherapy","Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy","","Immune checkpoint blockade improves outcomes in renal and bladder cancer, yet response rates remain limited, particularly in metastatic disease. This study investigates how the transcription factor STAT3 contributes to resistance to immunotherapy. Blood biomarker analyses compared nivolumab/ipilimumab responders and non-responders, revealing elevated proinflammatory mediators linked to STAT3 activation and tumor immunosuppression, especially in circulating myeloid cells. Using CpG-STAT3ASO for selective STAT3 knockdown, the work shows strong antitumor activity in syngeneic mouse models, enhanced by CpG-STAT3ASO with anti-PD1, via dendritic-cell and M1-macrophage activation, fewer Tregs, and CD8 T-cell expansion.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-stat3-in-tumor-associated-antigen-presenting-cells-as-a-strategy-for-kidney-and-bladder-cancer-immunotherapy/335862/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-stat3-in-tumor-associated-antigen-presenting-cells-as-a-strategy-for-kidney-and-bladder-cancer-immunotherapy/335862.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why focus on STAT3 in renal and bladder cancer immunotherapy resistance?","Question",{"text":112,"@type":113},"STAT3 is a master regulator of tumor immune evasion, but its role in resistance of renal or bladder cancers to immunotherapy was not well understood. This study examines STAT3’s contribution to limited response to checkpoint blockade.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What did the study find in blood biomarkers between responders and non-responders to ICB?",{"text":117,"@type":113},"Non-responders showed increased proinflammatory mediators, including IL-1RA, IL-6, IL-8 (and to a lesser extent IL-10). These changes relate to STAT3 activation and tumor immunosuppression.",{"name":119,"@type":110,"acceptedAnswer":120},"How does CpG-STAT3ASO affect antitumor immunity, and how does it compare with anti-PD1?",{"text":121,"@type":113},"CpG-STAT3ASO alone produced potent antitumor activity in syngeneic renal and bladder cancer mouse models compared with PD1 blockade alone. The CpG-STAT3ASO/anti-PD1 combination improved efficacy particularly for bladder tumors, linked to dendritic-cell and M1 macrophage activation, reduced Tregs, and increased CD8 T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335862,1790308574,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","TYPE Original Research PUBLISHED 08 January 2024  \nDOI 10.3389/fimmu.2023.1274781  \nOPEN ACCESS  \nEDITED BY  \nEnrique Podaza,  \nNewYork-Presbyterian, United States  \nREVIEWED BY Esteban Elias,  \nUniversity of Calgary, Canada Alessandra Mancino, San Raffaele Hospital (IRCCS), Italy  \n*CORRESPONDENCE Marice B. Alcantara  \n [malcantara@coh.org](malcantara@coh.org)[ ](malcantara@coh.org)Marcin Kortylewski  \n [mkortylewski@coh.org](mkortylewski@coh.org)  \nRECEIVED 08 August 2023  \nACCEPTED 11 December 2023  \nPUBLISHED 08 January 2024  \nCITATION  \nAlcantara MB, Tang WS, Wang D, Kaniowski D, Kang E, Dizman N, Chehrazi-Rafﬂe A, Meza L, Zengin Z, Hall J, Hsu J, Egelston C, Moreira D, Horsager A, Pal SK and Kortylewski M (2024) Targeting STAT3 in tumor-associated antigenpresenting cells as a strategy for kidney and bladder cancer immunotherapy.  \nFront. Immunol. 14:1274781 .  \ndoi: 10.3389/fimmu.2023.1274781  \nCOPYRIGHT  \n© 2024 Alcantara, Tang, Wang, Kaniowski, Kang, Dizman, Chehrazi-Rafﬂe, Meza, Zengin, Hall, Hsu, Egelston, Moreira, Horsager, Pal and Kortylewski. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeting STAT3 in tumorassociated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy  \nMarice B. Alcantara 1*, Wilson S. Tang 1, Dongfang Wang 1, Damian Kaniowski 1, Elaine Kang 1, Nazli Dizman 2,3, Alexander Chehrazi-Rafﬂe2, Luis Meza 2, Zeynep Zengin 2, Jeremy Hall 1, JoAnn Hsu 2, Colt Egelston 1, Dayson Moreira 1, Alan Horsager 4, Sumanta K. Pal 2 and Marcin Kortylewski 1*  \n1 Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Centre, Duarte, CA, United States, 2 Department of Medical Oncology, City of Hope National Medical Centre, Duarte, CA, United States, 3 MD Anderson Cancer Center, Department of Hematology and Oncology, Houston, TX, United States, 4 Duet Biotherapeutics, Pasadena, CA, United States  \nIntroduction: Immune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known master regulator of tumor immune evasion, little is known about the role of STAT3 in the resistance of renal or bladder cancers to immunotherapy.  \nMethods: To better understand immune alterations associated with ICB resistance, we assessed blood biomarkers in renal cancer patients classiﬁed as responders or non-responders to ﬁrst line nivolumab/ipilimumab immunotherapy.  \nResults: We observed that non-responders showed elevated levels of proinﬂammatory mediators, such as IL-1RA, IL-6, IL-8 and to lesser extent IL- 10, which are associated with STAT3 activation and tumor immunosuppression. In addition, we found STAT3 activation primarily in circulating myeloid immune cells such as tolerogenic MDSCs. To assess whether STAT3 inhibition within these cell subsets can promote antitumor immune responses and/or enhance sensitivity to ICB in vivo, we used an original antisense oligonucleotide (ASO) strategy for myeloid-cell selective STAT3 knockdown (CpG-STAT3ASO) . Our results in syngeneic models of renal and bladder cancers in mice demonstrated potent antitumor activity of CpG-STAT3ASO alone in contrast to PD1 blockade alone in both models. The CpG-STAT3ASO/anti-PD1 combination improved therapeutic efﬁcacy especially against bladder tumors. Therapeutic efﬁcacy correlated with activation of dendritic cells (DCs) and M1 macrophages in the tumor microenvironment, reduced percentages of regulatory T cells (Tregs) and the expansion of CD8 T ce","cbCaimclt2CCb8P0","https://ap.wps.com/l/cbCaimclt2CCb8P0","pdf",7015983,17,"English","# Introduction\n# Methods\n# Results\n# Discussion/Conclusion","[{\"question\":\"Why focus on STAT3 in renal and bladder cancer immunotherapy resistance?\",\"answer\":\"STAT3 is a master regulator of tumor immune evasion, but its role in resistance of renal or bladder cancers to immunotherapy was not well understood. This study examines STAT3’s contribution to limited response to checkpoint blockade.\"},{\"question\":\"What did the study find in blood biomarkers between responders and non-responders to ICB?\",\"answer\":\"Non-responders showed increased proinflammatory mediators, including IL-1RA, IL-6, IL-8 (and to a lesser extent IL-10). These changes relate to STAT3 activation and tumor immunosuppression.\"},{\"question\":\"How does CpG-STAT3ASO affect antitumor immunity, and how does it compare with anti-PD1?\",\"answer\":\"CpG-STAT3ASO alone produced potent antitumor activity in syngeneic renal and bladder cancer mouse models compared with PD1 blockade alone. The CpG-STAT3ASO/anti-PD1 combination improved efficacy particularly for bladder tumors, linked to dendritic-cell and M1 macrophage activation, reduced Tregs, and increased CD8 T cells.\"}]","Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy | PDF",1790012609,43]